High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy
Abstract Immunotherapy has emerged as an attractive option for patients with relapsed or refractory high-risk neuroblastoma (HRNB). Neuroblastoma (NB), a
נותנות החסות לאיגוד: